Provision of Preexposure Prophylaxis at the Portuguese National Health Service and Uptake in the Lisbon Cohort of Men Who Have Sex with Men.
HIV
Implementation
Men who have sex with men
Preexposure prophylaxis
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
07
12
2020
pubmed:
3
1
2021
medline:
1
5
2021
entrez:
2
1
2021
Statut:
ppublish
Résumé
We aimed to study the uptake of preexposure prophylaxis (PrEP) before and after its implementation in the Portuguese National Health Service (PNHS) among men who have sex with men (MSM). We studied 6164 participants in the Lisbon Cohort of MSM who participated between March 2014 and July 2019. 198 participants (3.2%) reported having recently used PrEP. Approximately one-third started PrEP after its implementation. PrEP uptake increased from 0.15% in 2014 to 5.36% in 2019. In their first use, 86 participants (70.5%) used it daily. How PrEP was obtained varied according to the timing of the first use: prescribed by a physician in Portugal (11.1% before vs 68.8% after implementation) and online (40.7% before vs 14.1% after). We observed an increase in the uptake and in the prescription by a physician, particularly after its implementation in the PNHS representing a change to a more equitable and safer way of using PrEP. Nuestro objetivo fue estudiar el uso de profilaxis pre exposición (PrEP) en hombres que tienen sexo con hombres (HSH), antes y después de su implementación en el Servicio Nacional de Salud de Portugal (PNHS). Estudiamos 6164 participantes de la Cohorte de HSH de Lisboa evaluados entre marzo de 2014 y julio de 2019. De los participantes, 198 (3,2%) indicaron haber utilizado PrEP recientemente. Aproximadamente un tercio comenzó con PrEP después de su implementación en el PNHS. El uso de PrEP aumentó del 0,15% en 2014 al 5,36% en 2019. En su primer uso, 86 participantes (70,5%) la usaron a diario. La forma en que se obtuvo la PrEP varió según el momento del primer uso: prescrito por un médico en Portugal (11,1% antes vs. 68,8% después de la implementación) y online (40,7% antes vs. 14,1% después). Observamos un aumento en el uso y en prescripción médica, particularmente después de su implementación en el PNHS, lo que representa un cambio hacia una forma más equitativa y segura de usar la PrEP.
Autres résumés
Type: Publisher
(spa)
Nuestro objetivo fue estudiar el uso de profilaxis pre exposición (PrEP) en hombres que tienen sexo con hombres (HSH), antes y después de su implementación en el Servicio Nacional de Salud de Portugal (PNHS). Estudiamos 6164 participantes de la Cohorte de HSH de Lisboa evaluados entre marzo de 2014 y julio de 2019. De los participantes, 198 (3,2%) indicaron haber utilizado PrEP recientemente. Aproximadamente un tercio comenzó con PrEP después de su implementación en el PNHS. El uso de PrEP aumentó del 0,15% en 2014 al 5,36% en 2019. En su primer uso, 86 participantes (70,5%) la usaron a diario. La forma en que se obtuvo la PrEP varió según el momento del primer uso: prescrito por un médico en Portugal (11,1% antes vs. 68,8% después de la implementación) y online (40,7% antes vs. 14,1% después). Observamos un aumento en el uso y en prescripción médica, particularmente después de su implementación en el PNHS, lo que representa un cambio hacia una forma más equitativa y segura de usar la PrEP.
Identifiants
pubmed: 33387137
doi: 10.1007/s10461-020-03127-2
pii: 10.1007/s10461-020-03127-2
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1975-1983Subventions
Organisme : Fundação para a Ciência e a Tecnologia
ID : UIDB/04750/2020
Organisme : Fundação para a Ciência e a Tecnologia
ID : SFRH/BD/112867/2015
Références
Molina JM, Capitant C, Spire B, ANRS IPERGAY Study Group, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.
doi: 10.1056/NEJMoa1506273
McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.
doi: 10.1016/S0140-6736(15)00056-2
Molina JM, Charreau I, Spire B, ANRS IPERGAY Study Group, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.
doi: 10.1016/S2352-3018(17)30089-9
United States Food and Drug Administration. Truvada for PrEP fact sheet: ensuring safe and proper use. United States Food and Drug Administration. 2012. https://www.fda.gov/media/83586/download . Accessed Feb 2020.
World Health Organization 2014 Policy brief: consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. World Health Organization https://www.who.int/hiv/pub/toolkits/keypopulations/en/ . Accessed Feb 2020
World Health Organization 2015 WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP): policy brief. World Health Organization https://www.who.int/hiv/pub/prep/policy-brief-prep-2015/en . Accessed Feb 2020
European Centre for Disease Prevention and Control 2015 Pre-exposure prophylaxis to prevent HIV among MSM in Europe. http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=780#sthash.RVE9DaCE.dpuf . Accessed Feb 2020
European Medicines Agency 2016 First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/07/WC500210885.pdf . Accessed Feb 2020
European Centre for Disease Prevention and Control (ECDC). Pre-exposure prophylaxis for HIV prevention in Europe and Central Asia. Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia – 2018/19 progress report. Stockholm: ECDC; 2019.
Circular Normativa Conjunta n.º 01/2018 do INFARMED/ACSS/DGS/SPMS de 1 de março de 2018, sobre o Programa de Acesso Precoce para Profilaxia de Pré-exposição da infeção por VIH-1 no Adulto. https://www.dgs.pt/directrizes-da-dgs/orientacoes-e-circulares-informativas/circular-informativa-conjunta-n-012018infarmeddgs-pdf.aspx . Accessed Jan 2020
Circular Normativa Conjunta n.º 02/2018 do INFARMED/ACSS/DGS/SPMS de 13 de março de 2018, sobre o Programa de Acesso Precoce para Profilaxia de Pré-exposição da infeção por VIH-1 no Adulto. https://www.dgs.pt/directrizes-da-dgs/normas-e-circulares-normativas/circular-normativa-conjunta-n-022018infarmedacssdgsspms-pdf.aspx . Accessed Jan 2020
Portugal. Ministério da Saúde. Direção-Geral da Saúde/Instituto Nacional de Saúde Doutor Ricardo Jorge. Infeção VIH e SIDA em Portugal - 2019. Lisboa: DGS/INSA; 2019. http://www.insa.min-saude.pt/wp-content/uploads/2019/11/RelatVIHSIDA2019.pdf . Accessed Dec 2019
Meireles P, Rocha M, Campos MJ, Barros H. PrEP use in Portugal while waiting for a policy. Abstracts of the HIV Glasgow supplement. J Int AIDS Soc 2016;19(Suppl 7). https://doi.org/10.7448/IAS.19.8.21487 . Available at: http://www.jiasociety.org/index.php/jias/article/view/21487 .
Ribeiro S, Rocha M. Pre-exposure prophylaxis counseling in a community sexual health clinic for men who have sex with men in Lisbon. Portugal Acta Med Port. 2019;32(6):441–7.
doi: 10.20344/amp.11474
Bourne A, Alba B, Garner A, Spiteri G, Pharris A, Noori T. Use of, and likelihood of using, HIV pre-exposure prophylaxis among men who have sex with men in Europe and Central Asia: findings from a 2017 large geosocial networking application survey. Sex Transm Infect. 2019;95(3):187–92.
doi: 10.1136/sextrans-2018-053705
The EMIS Network. EMIS-2017 – The European Men-Who-Have-Sex-With-Men Internet Survey. Key findings from 50 countries. Stockholm: European Centre for Disease Prevention and Control; 2019.
Meireles P, Lucas R, Martins A, et al. The lisbon cohort of men who have sex with men. BMJ Open. 2015;5(5):e007220.
doi: 10.1136/bmjopen-2014-007220
Lorente N, Folch C, Aussò S, et al. European Community Health Worker Online Survey Report (D8.5). Edited by CEEISCAT, Barcelona, 2019. Publications Office of the European Union, Luxembourg, 2019.
Portugal. Ministério da Saúde. Direção-Geral da Saúde. Norma nº 025/2017 de 28/11/2017 atualizada a 16/05/2018. Available from https://www.dgs.pt/directrizes-da-dgs/normas-e-circulares-normativas/norma-n-0252017-de-28112017-pdf.aspx . Accessed Mar 2019
Meireles P, Plankey M, Rocha M, et al. Eligibility for pre-exposure prophylaxis according to different guidelines in a cohort of HIV-negative men who have sex with men in lisbon. Portugal: Sex Res Social Policy; 2020.
doi: 10.1007/s13178-019-00426-9
Hayes R, Schmidt AJ, Pharris A, et al. Estimating the ‘PrEP gap’: how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. Euro Surveill. 2019;24(41):1900598.
doi: 10.2807/1560-7917.ES.2019.24.41.1900598
Kamitani E, Wichser ME, Adegbite AH, et al. Increasing prevalence of self-reported HIV preexposure prophylaxis use in published surveys: a systematic review and meta-analysis. AIDS. 2018;32(17):2633–5.
doi: 10.1097/QAD.0000000000001983
Reyniers T, Nöstlinger C, Laga M, et al. Choosing between daily and event-driven pre-exposure prophylaxis: results of a Belgian PrEP demonstration project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.
doi: 10.1097/QAI.0000000000001791
Hoornenborg E, Achterbergh RC, van der Loeff MFS, et al. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. J Int AIDS Soc. 2018;21(3):e25105.
doi: 10.1002/jia2.25105
Rivierez I, Quatremere G, Spire B, Ghosn J, Rojas CD. Lessons learned from the experiences of informal PrEP users in France: results from the ANRS-PrEPage study. AIDS Care. 2018;30(sup2):48–53.
doi: 10.1080/09540121.2018.1468014
Wang X, Nwokolo N, Korologou-Linden R, et al. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtricitabine in London: analysis of pharmacokinetics, safety and outcomes. HIV Med. 2018;19(1):1–6.
doi: 10.1111/hiv.12528
Brisson J. Ethical public health issues for the use of informal PrEP. Glob Public Health. 2018;13(10):1382–7.
doi: 10.1080/17441692.2017.1373139
Noori T, Pharris A. Meeting report: pre-exposure human immunodeficiency virus prophylaxis in the EU/EEA: challenges and opportunities, stockholm April 2016. Euro Surveill. 2016;21(25):30263.
doi: 10.2807/1560-7917.ES.2016.21.25.30263
Rojas Castro D, Delabre RM, Morel S, Michels D, Spire B. Community engagement in the provision of culturally competent HIV and STI prevention services: lessons from the French experience in the era of PrEP. J Int AIDS Soc. 2019;22(6):e25350.
pubmed: 31468710
pmcid: 6715944
Rojas Castro D, Quatremere G, Sagaon-Teyssier L, et al. Informal pre-exposure prophylaxis use in France: results from the flash PrEP survey (2014). HIV Med. 2017;18(4):308–10.
doi: 10.1111/hiv.12419
Lorenc T, Marrero-Guillamón I, Llewellyn A, et al. HIV testing among men who have sex with men (MSM): systematic review of qualitative evidence. Health Educ Res. 2011;26(5):834–46.
doi: 10.1093/her/cyr064
World Health Organization/Joint United Nations Programme on HIV/AIDS. Second generation surveillance for HIV: the next decade. http://www.who.int/reproductivehealth/publications/rtis/CDS_CSR_EDC_2000_5/en/ . Accessed Feb 2020
Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005;19(suppl 2):S67–72.
doi: 10.1097/01.aids.0000172879.20628.e1
Paquette D, De Wit J. Sampling methods used in developed countries for behavioural surveillance among men who have sex with men. AIDS Behav. 2010;14(6):1252–64.
doi: 10.1007/s10461-010-9743-7
World Health Organization/Joint United Nations Programme on HIV/AIDS 2011 Guidelines on surveillance among populations most at risk for HIV. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2011/20110518_Surveillance_among_most_at_risk.pdf . Accessed Feb 2020